EP Patent

EP2236151A1 — Melanocortin receptor ligands

Assigned to Ipsen Pharma SAS · Expires 2010-10-06 · 16y expired

What this patent protects

The present invention is directed to a compound according to the formula: €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2 and pharmaceutically-acceptable salts thereof. This compound acts as a ligand for one or more of the melanocortin receptors. The inventio…

USPTO Abstract

The present invention is directed to a compound according to the formula: €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2 and pharmaceutically-acceptable salts thereof. This compound acts as a ligand for one or more of the melanocortin receptors. The invention also relates to methods of using this compound to treat mammals and to pharmaceutical compositions comprising said compound.

Drugs covered by this patent

Patent Metadata

Patent number
EP2236151A1
Jurisdiction
EP
Classification
—
Expires
2010-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.